<DOC>
	<DOC>NCT01311648</DOC>
	<brief_summary>The objective of the study is to demonstrate the safety and efficacy of treatment with BAY81-8973 for prophylaxis and breakthrough bleeds in children with severe haemophilia A.</brief_summary>
	<brief_title>BAY81-8973 Pediatric Safety and Efficacy Trial</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male, aged &lt;/= 12 years Severe hemophilia A defined as &lt; 1% FVIII:C PTPs (previously treated patients) &gt; 50 Exposure days (ED) with any high purity FVIII, or PUPs (previously untreated patients) no prior exposure to any high purity FVIII MTPs (minimally treated patients) not previously having received more than 3 injections with any FVIII concentrate No current evidence or history of inhibitory antibody History of FVIII inhibitor formation Diagnosed with other bleeding disorder Platelet count &lt; 100000 cells/Î¼L Kidney or liver dysfunction Known hypersensitivity to any FVIII</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recombinant factor VIII</keyword>
	<keyword>pediatric use</keyword>
</DOC>